TO STUDY INCIDENCE OF MULTI DRUG RESISTANT TUBERCULOSIS IN MUMBAI
Keywords:Ionized, Rifampicin MDR-TB, Incident
Ionized and Rifampicin, the two most potent anti-tuberculosis drugs are rendered ineffective in Multidrug-resistant Tuberculosis (MDR-TB). India, China and Russia contribute to more than 62% of MDR-TB globally. In India, endemic areas like Mumbai are “hotspots” for the dissemination of MDR-TB. The aim of the study was to investigate the incidence of MDR-TB in cases of pulmonary tuberculosis in Mumbai. Total hundred and two clinical isolates of.Tuberculosiswas tested in the study. Drug susceptibility testing of these strains were carried by Resistance Ratio method to ant tuberculosis drugs namely Ionized, Streptomycin andEthambutol and by absolute concentration method for Rifampicinand Pyrazinamide. In our study highest resistance (46 %) was observed to INH followed by RF (42.16 %), SM (29.41 %) and EMB (25.49 %). While, resistance to Pyrazinamide (PZ) was least (7.8%). MDR TB cases were found to be 41.18%.There was significant difference between resistance pattern of INH and EMB, INH and SM, PZ and EMB, PZ and SM, EMB and RF, PZ and RF. (chi square with Yates correction =8.5, p<0.01).Detection of MDR TB strain would not only eliminate non-essential use of antibiotics, but would also help in the selection of most effective drug regimen and guide therapy in chronic cases.
Agrawal, S. K., & Shah, K. V. (2002). Study of drug resistance in previously treated TB patients in Gujrat , India. Inter. J. of Tuberc. and lung dis, 6(12:), 1098-1101..
Almeida, D., Rodrigues, C., Udwadia, Z. F., Lalvani, A., Gothi, G. D., Mehta, P., & Mehta, A. (2003). Incidence of Multidrug Resistant Tuberculosis in Urban and Rural India and Implications for prevention. Clin. Infect. Dis, e152-154.
Anuradha, B., Priya, V., Lakshmi, V., Akbar, Y., Aparna, S., Latha, G. S., & Murthy, K. (2006). Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001– 2003. The International Journal of Tuberculosis and Lung Disease, 10(1), 58-62.
Cannetti, G. S., Froman, J., Grosset, P., Hauduroy, M., Langerora, H. T., Mahler, G., . . . Sula, L. (1963). Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull. W.H.O. (Vol. 29, pp. 565-578).
Chandrasekaran, S., Jagota, P., Chaudhari, K. (1992). Initial drug resistance to antituberculosis drugs in urban and rural district tuberculosis programme. Ind J. Tub, 39(171).
Cornwall, J. (1997). Tuberculosis: a clinical problem of international importance.. Lancet, 349, 660-661.
Dam, T., Isa, M., & Bose, M. (2005). Drug-sensitivity profile of clinical Mycobacterium tuberculosis isolates–a retrospective study from a chest-disease institute in India. Journal of MedicalMicrobiology, 54(3), 269-271.
Datta, M., Radhamani, M. P., & Slvaraj, R. e. a. (1993). Critical assessment of smear –positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tubercle Lung Dis., 74, 180-186 .
Hemvani, N., Chitnis, D. S., Bhatia, G. C., & Sharma, N. (2001). Drug resistance among tubercle bacilli from pulmonary tuberculosis cases in central India. Indian J Med Sci, 55, 382– 392.
ICMR. (1968). First Drug resistance investigation. Ind. J. Med. Res., 56, 1617-1630.
ICMR. (1969). Second Drug resistance investigation. Indian J. Med Res, 57, 823-835.
Krishnaswamy, K. V., Venkatesan , R., & Parthasarathy, R. (1984). Prevalence of initial drug reistance among patients attending the clinics in Madras city. The Ind. J.Tuberc., 31, 164.
Mathur, M., Khatri, P., & Base, C. (2000). Drug resistance in tuberculosis patients in Jodhpur district. Indian Journal of MedicalSsciences, 54(2), 55.
Mitchison, D. A. (2005). Drug resistance in tuberculosis. Eur. Respir. J, 25, 376-379 Nunn, P., & Felten, M. (1994). Surveillance of resistance to antituberculosis drugs in developing countries. Tubercle and Lung Diseases 163-167.
Paramasivan, C. N. (1998). An overview on drug resistant tuberculosis in India. Lung India, 15(21).
Rosha, D., & Kataria, V. K. (2001). Impact of initial drug resistance pattern as the maintenance phase of short course chemotherapy with reference to the emergence of multi drug resistance. Ind. J. Tub, 48, 205.
Rosha, D. a. K., V.K. . (2001). Impact of initial drug resistance pattern as the maintenance phase of short course chemotherapy with reference to the emergence of multi drug resistance. Ind. J. Tub(48), 205.
Santha, T., Thomas, A., Chandrasekaran, V., Selvakumar, N., Gopi, P. G., Subramani, R.,Narayanan, P. R. (2006). Initial drug susceptibility profile of Mycobacterium tuberculosis among pulmonary tuberculosis patients diagnosed under TB control programme in a rural setting of south India. . Int J Tuberc Lung Dis 10, 52.
Shah, A. R., Agarwal, S. K., & Shah, K. V. (2002). Study of drug resistance in previously treated tuberculosis patients in Gujrat, India. Int J Tuberc Lung Dis, 6, 1098–1101.
Siddiqi, S., Aziz, A., Reggiardo, Z., & Middlebrook, G. (1981). Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis. Journal of clinical pathology, 34(8), 927-929.
Singh, S. (2004). HIV-TB Co-infection: A deadly combination. Paper presented at the International symposium on Tuberculosis research.
Trivedi, S. S. (1988). Primary Antituberculosis drug resistance and acquired rifampicin resistance in Gujrat, India. Tubercle 69, 37-42.
Vijay, S., Balasangameshwara, V. H., Jagannatha, P. S., Saroja, V. N., Shivashankar, & B. & Jagota, P. (2002). Re-treatment outcome of smear positive tuberculosis cases under DOTs in Bangalore city. Indian J Tuberc, 49, 195–204. .
WHO. (1993). The current global situation of the HIV/AIDS pandemic. Weekly Epidemiol 68, 195-196. .
World Health Organization, WHO Global Tuberculosis Report 2014),.
How to Cite
Copyright (c) 2015 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of Published Articles
Author(s) retain the article copyright and publishing rights without any restrictions.
All published work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.